Whitehawk Therapeutics price to sales ratio WHWK

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; not in our data today
Last meaningful: 26.4×; May 2026
4-year median: 4.8×
4-year range: 1.4× to 44.0×
Peer median: 1.4×

Whitehawk Therapeutics has no meaningful price to sales ratio today: it is not in our data for Oct 23, 2026.

It was last meaningful in May 2026, at 26.4×.

On the days it had one over the last 4 years, its median was 4.8×, from 1.4× in Jul 2024 to 44.0× in Sep 2022.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.4×	8.0×	27.1×
2025	8.7×	1.9×	8.7×
2024	3.2×	1.4×	3.3×
2023	2.1×	2.1×	28.7×
2022	28.5×	27.5×	44.0×

Against its peers

Companies in Drug Manufacturers - General nearest Whitehawk Therapeutics' size, closest first, today.

Company	Price to sales ratio
WHWKWhitehawk Therapeutics	n/m
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
ARVNArvinas	1.5×
SPROSpero Therapeutics	1.4×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ATNMActinium Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Whitehawk Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.